Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | MAVORIC trial: mogamulizumab for R/R CTC

At the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Pierluigi Porcu from Sidney Kimmel Cancer Center, Philadelphia, PA, describes the MAVORIC trial (NCT01728805) investigating the efficacy of vorinostat with the novel monoclonal antibody mogamulizumab in patients with refractory or relapsed cutaneous T-cell lyphoma (CTCL). Dr Pierluigi shares the trial design and highlights that further research is needed in order to tackle the unmet needs of CTCL.